Related Experiment Video
Updated: Aug 14, 2026
Coronary Artery Ligation and Intramyocardial Injection in a Murine Model of Infarction
Published on: June 7, 2011
Myocardial tissue engineering and regeneration as a therapeutic alternative to transplantation
A S Krupnick1, D Kreisel, M Riha
1Department of Surgery, Division of Cardiothoracic Surgery, Hospital of the University of Pennsylvania, 6 Silverstein Building, 3400 Spruce Street, Philadelphia, PA 19104, USA. krupnica@uphs.upenn.edu
Insights
Congestive heart failure from ischemic cardiomyopathy has limited treatments. New strategies like cell therapy and tissue engineering offer hope for heart failure patients, potentially replacing heart transplantation.
Area of Science:
- Cardiology
- Regenerative Medicine
- Transplantation Immunology
Background:
- Ischemic cardiomyopathy and congestive heart failure are leading causes of death.
- Current medical management provides only palliative care.
- Allogeneic heart transplantation is limited by donor organ availability and chronic rejection.
Purpose of the Study:
- To explore alternative therapeutic strategies for end-stage heart failure.
- To review emerging approaches beyond whole organ transplantation.
Main Methods:
- Review of current experimental efforts in cardiac regeneration.
- Focus on cellular cardiomyoplasty, myocardial tissue engineering, and myocardial regeneration.
Main Results:
- These experimental strategies represent promising alternatives to traditional transplantation.
- Cellular cardiomyoplasty, tissue engineering, and regeneration aim to restore heart function.
Conclusions:
- Novel therapeutic approaches are under development for end-stage heart failure.
- These regenerative strategies may offer future treatment options for patients suffering from heart failure.
Abstract:
Ischemic cardiomyopathy leading to congestive heart failure remains the leading source of morbidity and mortality in Western society and medical management of this condition offers only palliative treatment. While allogeneic heart transplantation can both extend and improve the quality of life for patients with end-stage heart failure, this therapeutic option is limited by donor organ shortage. Even after successful transplantation, chronic cardiac rejection in the form of cardiac allograft vasculopathy can severely limit the lifespan of the transplanted organ. Current experimental efforts focus on cellular cardiomyoplasty, myocardial tissue engineering, and myocardial regeneration as alternative approaches to whole organ transplantation. Such strategies may offer novel forms of therapy to patients with end-stage heart failure within the near future.
